scholarly journals Trajectories of adherence to adjuvant endocrine therapy for 5 years in women with breast cancer

2020 ◽  
Vol 30 (Supplement_5) ◽  
Author(s):  
V Memoli ◽  
G Lailler ◽  
C Le-Bihan ◽  
M K Bendiane ◽  
S Lauzier ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Side Effects ◽  
Endocrine Therapy ◽  
Adjuvant Endocrine Therapy ◽  
Factors Associated ◽  
High Adherence ◽  
Hormone Sensitive ◽  
Logistic Regressions ◽  
Optimal Adherence ◽  
Statistical Criteria

Abstract Background Adjuvant endocrine therapy (AET) is a daily oral medication prescribed for women with hormone-sensitive breast cancer (BC) to reduce recurrence and mortality risks. However, many women do not take AET daily or do not persist with AET for the recommended duration of at least 5 years. Our aims were to identify: 1) trajectories of AET adherence for the 5 years; 2) factors associated with these trajectories. Methods The French Cancer Cohort includes data on hospitalizations, ambulatory care and drug claims for all cancers diagnosed in France (SNDS database). Women diagnosed with a 1st non-metastatic BC in 2011 who had ≥ 1 AET claim within 12 months of surgery were included. For each woman, we estimated the monthly proportion of days covered (PDC) by an AET for 5 years after the first AET. Monthly PDCs were used to model AET adherence trajectories using group-based trajectory modeling. Statistical criteria were used to assess the suitability of the selected model. The factors associated with the trajectories were identified using multinomial logistic regressions. Results 33,260 women were included. A 6-trajectory model was selected: 1) Stop of AET in the 1st year (6.6%), 2) Adherence for 1 year and stop (5.7%), 3) Adherence for 2.5y and stop (6.3%), 4) High adherence for 4.5y and stop (8.3%), 5) Sub-optimal adherence for 5y (4.3%), 6) Very high adherence for 5y (68.8%). Factors associated with non-adherence trajectories are mainly extreme age (>70y) and switch in AET. Conclusions About 70% of women had an optimal adherence for 5 years. Our results showed that women who changed AET during the treatment course were at higher risk of non-adherence. Among non-adherent women, the switch in AET is frequent and probably often related to the management of side effects. Interventions to detect and manage these side effects may help to support women with AET use. Effective management of these effects during all the 5 years could be needed to maintain adherence. Key messages About 70% of women had an optimal adherence for 5 years. Women who changed AET during the treatment course were at higher risk of non-adherence.

Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer

2021 ◽  
Author(s):  
Maria Alice Franzoi ◽  
Elisa Agostinetto ◽  
Marta Perachino ◽  
Lucia Del Mastro ◽  
Evandro de Azambuja ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Side Effects ◽  
Endocrine Therapy ◽  
Adjuvant Endocrine Therapy ◽  
Evidence Based

scholarly journals A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy

2017 ◽  
Vol 9 (4) ◽  
pp. 269-285 ◽  
Author(s):  
Mariana S. Sousa ◽  
Michelle Peate ◽  
Sherin Jarvis ◽  
Martha Hickey ◽  
Michael Friedlander
Keyword(s):  
Breast Cancer ◽  
Side Effects ◽  
Endocrine Therapy ◽  
Breast Cancer Survivors ◽  
Early Recognition ◽  
Adjuvant Endocrine Therapy ◽  
Estrogen Deprivation ◽  
Natural Menopause ◽  
Appropriate Treatment ◽  
Multiple Domains

There is increasing attention and concern about managing the adverse effects of adjuvant endocrine therapy for women with early breast cancer as the side effects of therapy influence compliance and can impair quality of life (QoL). Most side effects associated with tamoxifen (TAM) and aromatase inhibitors (AIs) are directly related to estrogen deprivation, and the symptoms are similar to those experienced during natural menopause but appear to be more severe than that seen in the general population. Prolonged estrogen deprivation may lead to atrophy of the vulva, vagina, lower urinary tract and supporting pelvic structures, resulting in a range of genitourinary symptoms that can in turn lead to pain, discomfort, impairment of sexual function and negatively impact on multiple domains of QoL. The genitourinary side effects may be prevented, reduced and managed in most cases but this requires early recognition and appropriate treatment. We provide an overview of practical clinical approaches to understanding the pathophysiology and the management of genitourinary symptoms in postmenopausal women receiving adjuvant endocrine therapy for breast cancer.

scholarly journals Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer

2016 ◽  
Vol 27 (1) ◽  
pp. e12601 ◽  
Author(s):  
J. Brett ◽  
D. Fenlon ◽  
M. Boulton ◽  
N.J. Hulbert-Williams ◽  
F.M. Walter ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Endocrine Therapy ◽  
Adjuvant Endocrine Therapy ◽  
Factors Associated

Barriers to patient adherence with adjuvant endocrine therapy.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 6605-6605 ◽  
Author(s):  
Jennifer Michelle Duff ◽  
Hui Yan ◽  
Myron Chang ◽  
Eric Rosenberg ◽  
Karen Colleen Daily
Keyword(s):  
Breast Cancer ◽  
Side Effects ◽  
Endocrine Therapy ◽  
Text Messaging ◽  
Patient Adherence ◽  
Adjuvant Endocrine Therapy ◽  
Pharmacy Records ◽  
Electronic Reminder ◽  
Patient Reported ◽  
The Impact

6605 Background: Adjuvant endocrine therapy for hormone receptor positive breast cancer is essential to decreasing recurrence and improving survival. However, adherence to these drugs has been reported to be suboptimal, the impact of which on breast cancer outcomes is unknown. Multiple non-modifiable risk factors have been associated with nonadherence. Identifying patients’ self-reported reasons for not taking these drugs as prescribed may be crucial to improving adherence. Methods: We obtained data from 49 women prescribed tamoxifen, letrozole, anastrozole, or exemestane for stage I-III invasive breast cancer. Written surveys were provided during the patients’ medical oncology visits. Our study collected demographic data on patient characteristics associated with nonadherence. Patients were asked to report reasons for missing doses including forgetting to take the drug, side effects, cost, and barriers to refill. Patients described their degree of adherence by identifying how often they miss a dose as never, once per month, once per week, or more than once per week. We compared their self-reported adherence to pharmacy refill records. Results: More than half the women (26 of 49) report regularly missing doses of their drug over the last year. Of these, 22 miss once per month, 3 miss once per week, and 1 misses more than once per week. Despite this, pharmacy records verified consistent refills in all 26 less adherent patients over the past year. The most common reason identified for missed doses (21 of 26) was forgetting to take the drug, followed by barriers to refill and side effects. 57% of all patients favored receiving an electronic reminder via text messaging or email. Nonadherence was associated with polypharmacy and lower levels of education, income, and activity. Conclusions: Our study provides insight into patient reported reasons for nonadherence to adjuvant endocrine therapy. Our patients reported forgetting to take their drug as most problematic. Patients’ self-reported adherence was confirmed (96%) by pharmacy records. Most patients are interested in an electronic reminder system via e-mail or text messaging, even if they report complete adherence. This has potential to be a cost effective intervention.

Sign in / Sign up

Export Citation Format

Share Document